Chronic hepatitis C viral infection subverts vaccine-induced T-cell immunity in humans

Hepatology

Volumn 63, Issue 5, 2016, Pages 1455-1470

  Kelly, Christabel ^a,b   Swadling, Leo ^a   Capone, Stefania ^c   Brown, Anthony ^a   Richardson, Rachel ^a   Halliday, John ^a,b   von Delft, Annette ^a   Oo, Ye ^d   Mutimer, David ^d   Kurioka, Ayako ^a   Hartnell, Felicity ^a   Collier, Jane ^b   Ammendola, Virginia ^c   Sorbo, Mariarosaria Del ^c   Grazioli, Fabiana ^c   Esposito, Maria Luisa ^c   Marco, Stefania Di ^c   Siani, Loredana ^c   Traboni, Cinzia ^c   Hill, Adrian V S ^a,e   Colloca, Stefano ^c   Nicosia, Alfredo ^b,c,f,g   Cortese, Riccardo ^h   Folgori, Antonella ^c   Klenerman, Paul ^a,b,e   Barnes, Eleanor ^a,b,e   more..

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b NIHR OXFORD BIOMEDICAL RESEARCH CENTRE   (United Kingdom)

^c Viale Città d'Europa ^*  (Italy)

^d QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

^g UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^h Keires AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE; EPITOPE; GAMMA INTERFERON; HLA ANTIGEN CLASS 1; PEGINTERFERON ALPHA; RIBAVIRIN; ALPHA INTERFERON; HEPATITIS VACCINE; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2A; RECOMBINANT PROTEIN; RIBOFLAVIN;

ADULT; AGED; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHRONIC HEPATITIS C; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS REACTION; ENDOGENOUS VIRUS; ENZYME LINKED IMMUNOSPOT ASSAY; EX VIVO STUDY; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; HUMAN CELL; NONHUMAN; PERSISTENT VIRUS INFECTION; PHENOTYPE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY; T LYMPHOCYTE; VIRUS LOAD; ADENOVIRIDAE; AMINO ACID SEQUENCE; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; IMMUNOLOGY; MALE; MIDDLE AGED; MOLECULAR GENETICS; VACCINATION; VIROLOGY;

ADENOVIRIDAE; ADULT; AGED; AMINO ACID SEQUENCE; EPITOPES, T-LYMPHOCYTE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBOFLAVIN; T-LYMPHOCYTES; VACCINATION; VIRAL HEPATITIS VACCINES;

EID: 84958093632     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.28294     Document Type: Article

References (44)

1. Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 2015;61:77-87.
2. Razavi H, Elkhoury AC, Elbasha E, Estes C, Pasini K, Poynard T, et al. Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology 2013;57:2164-2170.
3. Barnes E, Folgori A, Capone S, Swadling L, Aston S, Kurioka A, et al. Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med 2012;4:115ra1.
4. Swadling L, Capone S, Antrobus RD, Brown A, Richardson R, Newell EW, et al. A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory. Sci Transl Med 2014;6:261ra153.
5. McKiernan SM, Hagan R, Curry M, McDonald GS, Kelly A, Nolan N, et al. Distinct MHC class I and II alleles are associated with hepatitis C viral clearance, originating from a single source. Hepatology 2004;40:108-114.
6. Grakoui A, Shoukry NH, Woollard DJ, Han JH, Hanson HL, Ghrayeb J, et al. HCV persistence and immune evasion in the absence of memory T cell help. Science 2003;302:659-662.
7. + T cells are required for protection from persistent hepatitis C virus infection. J Exp Med 2003;197:1645-1655.
8. + T cell responses during longitudinal study of acute human hepatitis C. Hepatology 2005;42:104-112.
9. Lechner F, Wong DK, Dunbar PR, Chapman R, Chung RT, Dohrenwend P, et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 2000;191:1499-1512.
10. Lauer GM, Barnes E, Lucas M, Timm J, Ouchi K, Kim AY, et al. High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection. Gastroenterology 2004;127:924-936.
11. + T cells. Eur J Immunol 2004;34:1570-1577.
12. Penna A, Pilli M, Zerbini A, Orlandini A, Mezzadri S, Sacchelli L, et al. Dysfunction and functional restoration of HCV-specific CD8 responses in chronic hepatitis C virus infection. Hepatology 2007;45:588-601.
13. Klade CS, Schuller E, Boehm T, von Gabain A, Manns MP. Sustained viral load reduction in treatment-naive HCV genotype 1 infected patients after therapeutic peptide vaccination. Vaccine 2012;30:2943-2950.
14. Habersetzer F, Baumert TF, Stoll-Keller F. GI-5005, a yeast vector vaccine expressing an NS3-core fusion protein for chronic HCV infection. Curr Opin Mol Ther 2009;11:456-462.
15. Gowans EJ, Roberts S, Jones K, Dinatale I, Latour PA, Chua B, et al. A phase I clinical trial of dendritic cell immunotherapy in HCV-infected individuals. J Hepatol 2010;53:599-607.
16. Alvarez-Lajonchere L, Shoukry NH, Gra B, Amador-Canizares Y, Helle F, Bedard N, et al. Immunogenicity of CIGB-230, a therapeutic DNA vaccine preparation, in HCV-chronically infected individuals in a phase I clinical trial. J Viral Hepat 2009;16:156-167.
17. Di Bisceglie AM, Janczweska-Kazek E, Habersetzer F, Mazur W, Stanciu C, Carreno V, et al. Efficacy of immunotherapy with TG4040, peg-interferon, and RIBavirin in a phase 2 study of patients with chronic HCV infection. Gastroenterology 2014;147:119-131.
18. Habersetzer F, Honnet G, Bain C, Maynard-Muet M, Leroy V, Zarski JP, et al. A poxvirus vaccine is safe, induces T-cell responses, and decreases viral load in patients with chronic hepatitis C. Gastroenterology 2011;141:890-899.
19. Wherry EJ, Blattman JN, Ahmed R. Low CD8 T-cell proliferative potential and high viral load limit the effectiveness of therapeutic vaccination. J Virol 2005;79:8960-8968.
20. Colloca S, Barnes E, Folgori A, Ammendola V, Capone S, Cirillo A, et al. Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci Transl Med 2012;4:115ra2.
21. Aste-AmŽzaga M, Bett AJ, Wang F, Casimiro DR, Antonello JM, Patel DK, et al. Quantitative adenovirus neutralization assays based on the secreted alkaline phosphatase reporter gene: application in epidemiologic studies and in the design of adenovector vaccines. Hum Gene Ther 2004;15:293-304.
22. Bucci C, von Delft A, Christian A, Flemming VM, Harrison A, Halliday J, et al. "Favourable" IL28B polymorphisms are associated with a marked increase in baseline viral load in hepatitis C virus subtype 3a infection and do not predict a sustained virological response after 24 weeks of therapy. J Gen Virol 2013;94:1259-1265.
23. Humphreys IS, von Delft A, Brown A, Hibbert L, Collier JD, Foster GR, et al. HCV genotype-3a T cell immunity: specificity, function and impact of therapy. Gut 2012;61:1589-1599.
24. Timm J, Lauer GM, Kavanagh DG, Sheridan I, Kim AY, Lucas M, et al. CD8 epitope escape and reversion in acute HCV infection. J Exp Med 2004;200:1593-1604.
25. + T cells enriched within the gut. Mucosal Immunol 2015; doi:10.1038/mi.2015.69.
26. Liang Y, Shilagard T, Xiao SY, Snyder N, Lau D, Cicalese L, et al. Visualizing hepatitis C virus infections in human liver by two-photon microscopy. Gastroenterology 2009;137:1448-1458.
27. Klenerman P, Hill A. T cells and viral persistence: lessons from diverse infections. Nat Immunol 2005;6:873-879.
28. Barnes E, Gelderblom HC, Humphreys I, Semmo N, Reesink HW, Beld MG, et al. Cellular immune responses during high-dose interferon-alpha induction therapy for hepatitis C virus infection. J Infect Dis 2009;199:819-828.
29. Barnes E, Salio M, Cerundolo V, Medlin J, Murphy S, Dusheiko G, et al. Impact of alpha interferon and ribavirin on the function of maturing dendritic cells. Antimicrob Agents Chemother 2004;48:3382-3389.
30. Bowen DG, Walker CM. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 2005;436:946-952.
31. Missale G, Pilli M, Zerbini A, Penna A, Ravanetti L, Barili V, et al. Lack of full CD8 functional restoration after antiviral treatment for acute and chronic hepatitis C virus infection. Gut 2012;61:1076-1084.
32. Klenerman P, Zinkernagel RM. Original antigenic sin impairs cytotoxic T lymphocyte responses to viruses bearing variant epitopes. Nature 1998;394:482-485.
33. Kelly C, Swadling L, Brown A, Capone S, Folgori A, Salio M, et al. Cross-reactivity of hepatitis C virus specific vaccine-induced T cells at immunodominant epitopes. Eur J Immunol 2015;45:309-316.
34. Wherry EJ, Blattman JN, Murali-Krishna K, van der Most R, Ahmed R. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J Virol 2003;77:4911-4927.
35. + T cells. J Immunol 2004;172:1744-1753.
36. Buxton JA, Kim JH. Hepatitis A and hepatitis B vaccination responses in persons with chronic hepatitis C infections: a review of the evidence and current recommendations. Can J Infect Dis Med Microbiol 2008;19:197-202.
37. + T cell responses are primed during acute hepatitis C infection, but rapidly disappear from human blood with viral persistence. J Exp Med 2012;209:61-75.
38. Duggal P, Thio CL, Wojcik GL, Goedert JJ, Mangia A, Latanich R, et al. Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts. Ann Intern Med 2013;158:235-245.
39. Cox AL, Netski DM, Mosbruger T, Sherman SG, Strathdee S, Ompad D, et al. Prospective evaluation of community-acquired acute-phase hepatitis C virus infection. Clin Infect Dis 2005;40:951-958.
40. Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014;370:1483-1493.
41. Martin NK, Hickman M, Hutchinson SJ, Goldberg DJ, Vickerman P. Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. Clin Infect Dis 2013;57(Suppl. 2):S39-S45.
42. Serti E, Chepa-Lotrea X, Kim YJ, Keane M, Fryzek N, Liang TJ, et al. Successful interferon-free therapy of chronic hepatitis C virus infection normalizes natural killer cell function. Gastroenterology 2015;149:190-200.
43. + T cell function by interferon-free therapy. J Hepatol 2014;61:538-543.
44. Gardiner D, Lalezari J, Lawitz E, DiMicco M, Ghalib R, Reddy KR, et al. A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection. PloS One 2013;8:e63818.